We Offer Worldwide Shipping
Login Wishlist

Pazopanib

$120

  • Brand : BIOFRON

  • Catalogue Number : BN-O1251

  • Specification : 98%(HPLC)

  • CAS number : 444731-52-6

  • Formula : C21H23N7O2S

  • Molecular Weight : 437.52

  • PUBCHEM ID : 10113978

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1251

Analysis Method

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

437.52

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N

Synonyms

5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide/Pazopanib(GW786034)/Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-/5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide/Pazopanib

IUPAC Name

Density

1.4±0.1 g/cm3

Solubility

Flash Point

394.6±35.7 °C

Boiling Point

728.8±70.0 °C at 760 mmHg

Melting Point

285-289°C (dec.)

InChl

InChl Key

CUIHSIWYWATEQL-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:444731-52-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29999917

Title

Pazopanib.

Publish date

2006

PMID

31403280

Abstract

Mass spectrometry imaging (MSI) has the potential to reveal the localization of thousands of biomolecules such as metabolites and lipids in tissue sections. The increase in both mass and spatial resolution of today’s instruments brings on considerable challenges in terms of data processing; accurately extracting meaningful signals from the large data sets generated by MSI without losing information that could be clinically relevant is one of the most fundamental tasks of analysis software. Ion images of the biomolecules are generated by visualizing their intensities in 2-D space using mass spectra collected across the tissue section. The intensities are often calculated by summing each compound’s signal between predefined sets of borders (bins) in the m/z dimension. This approach, however, can result in mixed signals from different compounds in the same bin or splitting the signal from one compound between two adjacent bins, leading to low quality ion images. To remedy this problem, we propose a novel data processing approach. Our approach consists of a sensitive peak detection method able to discover both faint and localized signals by utilizing clusterwise kernel density estimates (KDEs) of peak distributions. We show that our method can recall more ground-truth molecules, molecule fragments, and isotopes than existing methods based on binning. Furthermore, it automatically detects previously reported molecular ions of lipids, including those close in m/z, in an experimental data set.

Title

Clusterwise Peak Detection and Filtering Based on Spatial Distribution To Efficiently Mine Mass Spectrometry Imaging Data

Author

Jonatan O. Eriksson,† Melinda Rezeli,† Max Hefner,† Gyorgy Marko-Varga,† and Peter Horvatovich*‡†

Publish date

2019 Sep 17

PMID

28042343

Abstract

Resistance mechanisms against antiangiogenic drugs are unclear. Here, we correlated the antitumor and antivascular properties of five different antiangiogenic receptor tyrosine kinase inhibitors (RTKIs) (motesanib, pazopanib, sorafenib, sunitinib, vatalanib) with their intratumoral distribution data obtained by matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI). In the first mouse model, only sunitinib exhibited broad-spectrum antivascular and antitumor activities by simultaneously suppressing vascular endothelial growth factor receptor-2 (VEGFR2) and desmin expression, and by increasing intratumoral hypoxia and inhibiting both tumor growth and vascularisation significantly. Importantly, the highest and most homogeneous intratumoral drug concentrations have been found in sunitinib-treated animals. In another animal model, where – in contrast to the first model – vatalanib was detectable at homogeneously high intratumoral concentrations, the drug significantly reduced tumor growth and angiogenesis. In conclusion, the tumor tissue penetration and thus the antiangiogenic and antitumor potential of antiangiogenic RTKIs vary among the tumor models and our study demonstrates the potential of MALDI-MSI to predict the efficacy of unlabelled small molecule antiangiogenic drugs in malignant tissue. Our approach is thus a major technical and preclinical advance demonstrating that primary resistance to angiogenesis inhibitors involves limited tumor tissue drug penetration. We also conclude that MALDI-MSI may significantly contribute to the improvement of antivascular cancer therapies.

KEYWORDS

matrix assisted laser desorption ionization, imaging mass spectrometry, angiogenesis, receptor tyrosine kinase inhibitor, resistance, cancer

Title

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors

Author

Szilvia Torok,1,2,3,4 Melinda Rezeli,3 Olga Kelemen,1,3 Akos Vegvari,3,5 Kenichi Watanabe,3 Yutaka Sugihara,3,6 Anna Tisza,1 Timea Marton,1 Ildiko Kovacs,1 Jozsef Tovari,7 Viktoria Laszlo,2,8 Thomas H. Helbich,8 Balazs Hegedus,2,9,10 Thomas Klikovits,2 Mir Alireza Hoda,2 Walter Klepetko,2 Sandor Paku,10,11 Gyorgy Marko-Varga,3,12,✉ and Balazs Dome1,2,4,8,✉

Publish date

2017;


Description :

Empty ...